Organisation paid for research Program year 2023 Source: CMS Open Payments

Manhattan Behavioral Medicine PLLC

Neither a doctor nor a teaching hospital

Research payments

$488,716

113 payments

Through program year 2023, Manhattan Behavioral Medicine PLLC is reported as receiving $488,716 in research payments, across 113 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $9,977 1
2022 Research $9,521 4
2021 Research $82,946 26
2020 Research $148,229 28
2019 Research $238,044 54

Breakdown

Who paid Research payments · program years 2019–2023
  1. Allergan Inc. $254,172 44 payments
  2. H. Lundbeck A S $122,800 18 payments
  3. Supernus Pharmaceuticals, Inc. $39,634 9 payments
  4. Avanir Pharmaceuticals, Inc. $32,713 12 payments
  5. Sage Therapeutics, Inc. $11,937 2 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $6,998 1 payment
  7. ACADIA Pharmaceuticals Inc $4,692 1 payment
  8. Sunovion Pharmaceuticals Inc. $4,248 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $3,602 2 payments
  10. Neurocrine Biosciences, Inc. $3,179 18 payments
Studies the money was for Research payments · program years 2019–2023
  1. Phase 4 (PMR Pediatric Gad) $109,255 15 payments
  2. Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD $98,448 1 payment
  3. Phase 4 (PMR Pediatric Gad) $66,904 15 payments
  4. Phase 4 PMR Pediatric GAD $55,829 7 payments
  5. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $30,021 3 payments
  6. 15-Avp-786-303 $21,763 8 payments
  7. Active Reference (Fluoxetine) Fixed-Dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) $11,880 10 payments
  8. A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO in a Home Setting $9,977 1 payment
  9. An Open-Label Long-Term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder $7,305 1 payment
  10. A Multicenter, Double Blind, Placebo and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder $7,213 1 payment
What the money was spent on Research payments · program years 2019–2023
  1. Other $3,602 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record